Nash Meeting News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nash meeting. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nash Meeting Today - Breaking & Trending Today

Pirtobrutinib Monotherapy Demonstrates Early Activity in R/R Follicular Lymphoma

Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma. ....

Niravn Shah , College Of Wisconsin , Medical College , Ann Arbor , Nash Meeting , Follicular Lymphoma , Phase 1 2 Bruin Trial Nct03740529 ,

Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population. ....

Mazyar Shadman , Fred Hutch Cancer Center , Network Endowed Chair , B Cell Malignancies , Phase 2 Bgb 3111 215 Study , Intolerant To Acalabrutinib , Nash Meeting ,

Golidocitinib Demonstrates Efficacy in Relapsed/Refractory PTCL

Golidocitinib displayed antitumor activity and an acceptable safety profile in patients with refractory/relapsed peripheral T-cell lymphoma, according to data from the pivotal phase 2 JACKPOT8 study. ....

Yuqin Song , University Cancer Hospital , Peking University Cancer Hospital , Nash Meeting , Refractory Relapsed Peripheralt Cell Lymphoma , Jackpot8 Study ,